|
S. No. |
Antimicrobial |
Type of Response |
| Gr. I
Control |
Gr. II |
Gr. III
Day 10 |
| Day 5 |
Day 10 |
| 1. |
Amikacin |
≤16 |
≤16 |
≤16 |
≤16 |
| 2. |
Amoxicillin/K-Clavulanate |
>16/8 |
>16/8 |
>16/8 |
>16/8 |
| 3. |
Ampicillin/Sulbactam |
>16/8 |
>16/8 |
>16/8 |
>16/8 |
| 4. |
Ampicillin |
>16 |
>16 |
>16 |
>16 |
| 5. |
Aztreonam |
>16 |
>16 |
>16 |
≤8 |
| 6. |
Cefazolin |
>16 |
>16 |
>16 |
>16 |
| 7. |
Cefepime |
≤8 |
≤8 |
≤8 |
≤8 |
| 8. |
Cefotaxime |
≤8 |
32 |
32 |
≤8 |
| 9. |
Cefotetan |
>32 |
>32 |
>32 |
>32 |
| 10. |
Cefoxitin |
>16 |
>16 |
>16 |
>16 |
| 11. |
Ceftazidime |
16 |
16 |
16 |
≤8 |
| 12. |
Ceftriaxone |
≤8 |
32 |
32 |
≤8 |
| 13. |
Cefuroxime |
>16 |
>16 |
>16 |
>16 |
| 14. |
Cephalothin |
>16 |
>16 |
>16 |
>16 |
| 15. |
Chloramphenicol |
≤8 |
≤8 |
≤8 |
≤8 |
| 16. |
Ciprofloxacin |
2 |
2 |
2 |
≤1 |
| 17. |
Gatifloxacin |
≤2 |
≤2 |
≤2 |
≤2 |
| 18. |
Gentamicin |
≤4 |
≤4 |
≤4 |
≤4 |
| 19. |
Imipenem |
≤4 |
≤4 |
≤4 |
≤4 |
| 20. |
Levofloxacin |
≤2 |
≤2 |
≤2 |
≤2 |
| 21. |
Meropenem |
≤4 |
≤4 |
≤4 |
≤4 |
| 22. |
Moxifloxacin |
≤2 |
≤2 |
≤2 |
≤2 |
| 23. |
Piperacillin |
≤16 |
≤16 |
≤16 |
≤16 |
| 24. |
Piperacillin/Tazobactam |
≤16 |
≤16 |
≤16 |
≤16 |
| 25. |
Tetracycline |
≤4 |
≤4 |
≤4 |
≤4 |
| 26. |
Ticarcillin/K-Clavulanate |
>64 |
64 |
64 |
64 |
| 27. |
Tobramycin |
≤4 |
≤4 |
≤4 |
≤4 |
| 28. |
Trimethoprim/Sulfamethoxazole |
≤2/38 |
≤2/38 |
≤2/38 |
≤2/38 |
| MIC data are presented in μg/mL; Gr.: Group |
|
